Aurora Private Wealth Inc. Buys New Position in Bristol Myers Squibb Company (NYSE:BMY)

Aurora Private Wealth Inc. acquired a new position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 1st quarter, according to its most recent filing with the SEC. The fund acquired 99,019 shares of the biopharmaceutical company's stock, valued at approximately $6,039,000.

A number of other large investors have also recently added to or reduced their stakes in BMY. Norges Bank acquired a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at approximately $1,989,525,000. Ameriprise Financial Inc. lifted its position in shares of Bristol Myers Squibb by 59.9% in the fourth quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock valued at $1,814,341,000 after acquiring an additional 12,011,983 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in shares of Bristol Myers Squibb by 701.2% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,470,106 shares of the biopharmaceutical company's stock worth $705,309,000 after purchasing an additional 10,913,708 shares during the last quarter. Wellington Management Group LLP boosted its position in Bristol Myers Squibb by 3,880.0% during the fourth quarter. Wellington Management Group LLP now owns 5,977,505 shares of the biopharmaceutical company's stock worth $338,088,000 after acquiring an additional 5,827,317 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Bristol Myers Squibb in the fourth quarter valued at $257,618,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Stock Performance

NYSE:BMY traded up $0.00 during trading hours on Thursday, reaching $46.68. 7,321,269 shares of the stock were exchanged, compared to its average volume of 12,897,945. The stock has a market capitalization of $95.01 billion, a P/E ratio of 17.48, a P/E/G ratio of 1.38 and a beta of 0.38. The firm has a 50 day simple moving average of $48.01 and a 200-day simple moving average of $54.11. The company has a quick ratio of 1.17, a current ratio of 1.28 and a debt-to-equity ratio of 2.65. Bristol Myers Squibb Company has a 52 week low of $39.35 and a 52 week high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.30. The firm had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The firm's revenue for the quarter was down 5.6% on a year-over-year basis. During the same period last year, the business posted ($4.40) earnings per share. As a group, sell-side analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd will be paid a $0.62 dividend. The ex-dividend date is Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 5.31%. Bristol Myers Squibb's payout ratio is currently 92.88%.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on BMY. Cantor Fitzgerald reiterated a "neutral" rating and issued a $55.00 price target on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. The Goldman Sachs Group restated a "neutral" rating and issued a $55.00 price objective (down from $67.00) on shares of Bristol Myers Squibb in a report on Tuesday, April 8th. Jefferies Financial Group decreased their target price on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. Argus upgraded shares of Bristol Myers Squibb to a "hold" rating in a report on Friday, April 25th. Finally, Piper Sandler initiated coverage on Bristol Myers Squibb in a report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $58.00.

Insider Activity

In other news, EVP Samit Hirawat bought 4,250 shares of Bristol Myers Squibb stock in a transaction on Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the purchase, the executive vice president now directly owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.09% of the company's stock.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.